Metsera to Present at Upcoming September Investor Conferences
Metsera (Nasdaq: MTSR), a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, has announced upcoming investor conference presentations. CEO Whit Bernard will present at two major healthcare conferences in September:
- Cantor Global Healthcare Conference on September 3 at 3:20-3:50 PM EDT
- Wells Fargo Healthcare Conference on September 4 at 4:30-5:05 PM EDT
Investors can access live webcasts and replays of both presentations through the Events page in the Investors & News section at investors.metsera.com.
Metsera (Nasdaq: MTSR), azienda biofarmaceutica in fase clinica specializzata in obesità e malattie metaboliche, ha annunciato le prossime presentazioni per investitori. Il CEO Whit Bernard sarà relatore a due importanti conferenze sanitarie a settembre:
- Cantor Global Healthcare Conference il 3 settembre dalle 15:20 alle 15:50 EDT
- Wells Fargo Healthcare Conference il 4 settembre dalle 16:30 alle 17:05 EDT
Gli investitori possono seguire le dirette e le registrazioni di entrambe le presentazioni tramite la pagina Events nella sezione Investors & News su investors.metsera.com.
Metsera (Nasdaq: MTSR), una compañía biofarmacéutica en fase clínica centrada en la obesidad y las enfermedades metabólicas, ha anunciado próximas presentaciones para inversores. El CEO Whit Bernard participará como ponente en dos importantes conferencias de salud en septiembre:
- Cantor Global Healthcare Conference el 3 de septiembre de 3:20 a 3:50 PM EDT
- Wells Fargo Healthcare Conference el 4 de septiembre de 4:30 a 5:05 PM EDT
Los inversores pueden acceder a las transmisiones en vivo y a las repeticiones de ambas presentaciones en la página Events de la sección Investors & News en investors.metsera.com.
Metsera (Nasdaq: MTSR), 비만 및 대사 질환에 주력하는 임상 단계 생명공학 기업이 투자자 대상 발표 일정을 발표했습니다. CEO Whit Bernard는 9월에 열리는 두 개의 주요 헬스케어 콘퍼런스에서 발표할 예정입니다:
- 9월 3일 Cantor Global Healthcare Conference, 오후 3:20–3:50 EDT
- 9월 4일 Wells Fargo Healthcare Conference, 오후 4:30–5:05 EDT
투자자들은 investors.metsera.com의 Investors & News 섹션 내 Events 페이지에서 두 발표의 생중계 및 재생 영상을 시청할 수 있습니다.
Metsera (Nasdaq: MTSR), société biopharmaceutique en phase clinique spécialisée dans l'obésité et les maladies métaboliques, a annoncé ses prochaines présentations aux investisseurs. Le PDG Whit Bernard interviendra lors de deux grandes conférences santé en septembre :
- Cantor Global Healthcare Conference le 3 septembre de 15h20 à 15h50 EDT
- Wells Fargo Healthcare Conference le 4 septembre de 16h30 à 17h05 EDT
Les investisseurs peuvent accéder aux webdiffusions en direct et aux replays des deux présentations via la page Events dans la section Investors & News sur investors.metsera.com.
Metsera (Nasdaq: MTSR), ein biopharmazeutisches Unternehmen in klinischer Entwicklung mit Fokus auf Adipositas und Stoffwechselerkrankungen, hat seine bevorstehenden Investorenpräsentationen angekündigt. CEO Whit Bernard wird im September auf zwei großen Gesundheitskonferenzen sprechen:
- Cantor Global Healthcare Conference am 3. September von 15:20–15:50 EDT
- Wells Fargo Healthcare Conference am 4. September von 16:30–17:05 EDT
Investoren können Live-Streams und Aufzeichnungen beider Präsentationen über die Events-Seite im Bereich Investors & News auf investors.metsera.com abrufen.
- None.
- None.
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the following investor conferences:
- Cantor Global Healthcare Conference 2025
Wednesday, September 3
3:20 – 3:50 P.M. EDT - Wells Fargo 2025 Healthcare Conference
Thursday, September 4
4:30 – 5:05 P.M. EDT
A live webcast and replay of the presentations will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com.
About Metsera
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at www.metsera.com and follow us on LinkedIn and X.
Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at investors.metsera.com. In addition, you may sign up to automatically receive email alerts and other information about the Company by using the “Email Alerts” option on the Investors & Media page and submitting your email address.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act”). Examples of such statements include, but are not limited to, statements relating to Metsera's expectations regarding participation in the Cantor Global Healthcare Conference 2025 and the Wells Fargo 2025 Healthcare Conference, its research and development activities, and its product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Metsera’s business outlined in Metsera’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of its Annual Report on Form 10-K for the year ended December 31, 2024. Forward-looking statements are not guarantees of future performance, and Metsera’s actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Metsera makes in this press release speak only as of the date of this press release. Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Jono Emmett
Metsera
media@metsera.com
